Jyong Biotech (MENS) Liabilities and Shareholders Equity (2024 - 2025)
Jyong Biotech's (MENS) quarterly Liabilities and Shareholders Equity came in at $20.8 million in Q4 2025, up 226.39% year-on-year from $6.4 million in Q4 2024, and down 44.84% quarter-over-quarter from $37.7 million in Q2 2025.
Jyong Biotech (MENS) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Jyong Biotech's Liabilities and Shareholders Equity history runs 2 years deep, the most recent figure standing at $20.8 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 20.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.78 Mn |
| Jun 30, 2025 | 37.67 Mn |
| Dec 31, 2024 | 6.37 Mn |